J. Porter

发表

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

E. Vichinsky, A. Kutlar, T. Coates, 2011, British journal of haematology.

Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia.

C. Currie, S. Jenkins-Jones, S. Holden, 2018, European journal of endocrinology.

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia

A. Juul, P. Touraine, A. Brac de la Perrière, 2021, The Journal of clinical endocrinology and metabolism.

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

H. Cario, E. Vichinsky, M. Cappellini, 2007, Clinical therapeutics.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

P. Marks, O. Onyekwere, P. Swerdlow, 2007, British journal of haematology.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

K. Dufu, J. Howard, P. Telfer, 2019, Blood.

Consequences and management of iron overload in sickle cell disease.

J. Porter, M. Garbowski, 2013, Hematology. American Society of Hematology. Education Program.

Secondary iron overload.

N. Olivieri, J. Kushner, J. Porter, 2001, Hematology. American Society of Hematology. Education Program.

Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis

P. Marks, O. Onyekwere, P. Swerdlow, 2008, Acta Haematologica.

A Biopredictive In Vitro Approach for Assessing Compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing Vehicles

S. Klein, Daniel N Margetson, J. Porter, 2020, Pharmaceutical Research.

Extubation in neurocritical care patients: the ENIO international prospective study

R. Stevens, P. Pelosi, G. Citerio, 2022, Intensive Care Medicine.

PPH Butterfly: a novel device to treat postpartum haemorrhage through uterine compression

T. Lavender, A. Weeks, J. Porter, 2017, BMJ Innovations.

FBS0701, a novel oral iron chelator, in transfusional iron overload A phase 2 study of the safety, tolerability and pharmacodynamics of

E. Neufeld, V. Viprakasit, R. Galanello, 2012 .

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

S. Perrotta, P. Marks, M. Cappellini, 2006, Blood.

An oral lipidic native testosterone formulation that is absorbed independent of food

B. Keevil, J. Newell-Price, R. Ross, 2021, European journal of endocrinology.

A Prospective Study of Children Aged 0–8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules

S. Wiegand, H. Krude, K. Braune, 2020, The Journal of clinical endocrinology and metabolism.

Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme)

R. Ross, J. Porter, M. Withe, 2018, Expert review of endocrinology & metabolism.

Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

J. Porter, 2018, Hematology. American Society of Hematology. Education Program.

Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.

Zinnia P. Parra-Guillen, W. Huisinga, C. Kloft, 2020, European journal of endocrinology.

Is physiological glucocorticoid replacement important in children?

J. Blair, R. Ross, J. Porter, 2016, Archives of Disease in Childhood.

Are the risks of treatment to cure a child with severe sickle cell disease too high?

A. Vora, D. Rees, M. de Montalembert, 2017, British Medical Journal.

Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency

S. Wiegand, H. Krude, R. Ross, 2018, Clinical endocrinology.

Hydrocortisone granules in capsules for opening (Alkindi) as replacement therapy in pediatric patients with adrenal insufficiency

R. Ross, J. Porter, L. Parviainen, 2021 .

Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency

S. Wiegand, H. Krude, R. Ross, 2019, Endocrine Abstracts.

Adrenal Insufficiency in Young Children: a Mixed Methods Study of Parents’ Experiences

S. Dixon, Amy Simpson, R. Ross, 2018, Journal of Genetic Counseling.

Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'.

Zinnia P. Parra-Guillen, W. Huisinga, C. Kloft, 2020, European journal of endocrinology.

Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency.

T. Johnson, H. Burt, J. Bonner, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Efficacy and Safety of Deferasirox (Exjade®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis

M. Cappellini, R. Galanello, A. Piga, 2008 .

Safety of Deferasirox (Exjade®) in Patients with Transfusion-Dependent Anemias and Iron Overload Who Achieve Serum Ferritin Levels <1000 Ng/Ml during Long-Term Treatment

J. Ford, M. Cappellini, A. Piga, 2008 .

Utilization of mechanical power and associations with clinical outcomes in brain injured patients: a secondary analysis of the extubation strategies in neuro-intensive care unit patients and associations with outcome (ENIO) trial

R. Stevens, P. Pelosi, G. Citerio, 2023, Critical Care.

Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.

P. Touraine, A. Mallappa, D. Merke, 2023, European journal of endocrinology.